We are seeking matching funds for our tuberculosis (fl3)vaccine efforts, involving both pre-clinical and clinical studies. Specifically, these include the optimization of vaccine constructs and delivery systems in animal models to maximize protective efficacy. We will, using the priority Mtb antigens we have identified, produce poly-proteins with high expression levels in recombinant systems suitable for manufacture and use these protein antigens with state-of-the-art adjuvants, already tested in the clinic, along with delivery systems chosen to maximize T cell responses. We will focus vaccine studies in the guinea pig and primate systems, as well as use mice to characterize immune responses induced by the experimental vaccines. Finally, we will perform a clinical trial with a poly-protein construct consisting of three Mtb antigens produced as a single protein, formulated with AS2, an adjuvant shown to be safe and effective in the clinic. The purpose of the trial is to show safety and immunogenicity of a promising vaccine in normal human subjects.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
NIH Challenge Grants and Partnerships Program - Phase II-Coop.Agreement (UC1)
Project #
1UC1AI049505-01
Application #
6325184
Study Section
Special Emphasis Panel (ZAI1-PRJ-M (S1))
Program Officer
Sizemore, Christine F
Project Start
2000-09-30
Project End
2005-05-31
Budget Start
2000-09-30
Budget End
2005-05-31
Support Year
1
Fiscal Year
2000
Total Cost
$2,316,340
Indirect Cost
Name
Corixa Corporation
Department
Type
DUNS #
City
Hamilton
State
MT
Country
United States
Zip Code
59840
Reed, Steven G; Coler, Rhea N; Dalemans, Wilfried et al. (2009) Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci U S A 106:2301-6
Skeiky, Yasir A W; Alderson, Mark R; Ovendale, Pamela J et al. (2004) Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172:7618-28
Brandt, Lise; Skeiky, Yasir A W; Alderson, Mark R et al. (2004) The protective effect of the Mycobacterium bovis BCG vaccine is increased by coadministration with the Mycobacterium tuberculosis 72-kilodalton fusion polyprotein Mtb72F in M. tuberculosis-infected guinea pigs. Infect Immun 72:6622-32
Reed, Steven G; Campos-Neto, Antonio (2003) Vaccines for parasitic and bacterial diseases. Curr Opin Immunol 15:456-60
Reed, S G; Alderson, M R; Dalemans, W et al. (2003) Prospects for a better vaccine against tuberculosis. Tuberculosis (Edinb) 83:213-9